Nicht fernmetastasiertes kastrationsresistentes Prostatakarzinom (M0CRPC)

Zusammenfassung

Das Auftreten von Fernmetastasen stellt beim nicht fernmetastasierten kastrationsresistenten Prostatakarzinom (M0CRPC) einen prognostisch ungünstigen Wendepunkt dar. Dabei haben M0CRPC-Patienten mit kurzer PSA-Verdopplungszeit ein besonders hohes Progressionsrisiko. Für diese Patienten gab es lange Zeit, bis auf das abwartende Beobachten unter Beibehaltung der klassischen Androgendeprivationstherapie (ADT), keine weiteren Therapieoptionen. Das seit Januar 2019 verfügbare Next-Generation Antiandrogen Apalutamid verlängerte in der Zulassungsstudie SPARTAN beim Hochrisiko-M0CRPC das metastasenfreie Überleben signifikant gegenüber Placebo. Die vorliegenden Patientenfälle aus der SPARTAN-Studie und dem Apalutamid Härtefallprogramm sind Beispiele für die positiven Effekte, die Apalutamid im M0CRPC-Stadium erzielen kann.

Abstract

The occurrence of distant metastases represents a prognostically unfavourable turning point in non-metastatic castration-resistant prostate cancer (M0CRPC). M0CRPC patients with a short PSA doubling time have a particularly high risk of progression. For a long time, there was no further treatment option for these patients apart from watchful waiting while maintaining classic androgen deprivation therapy (ADT). Apalutamide, a next-generation anti-androgen available since January 2019, significantly increased metastasis-free survival compared with placebo in the pivotal SPARTAN trial in patients with high-risk M0CRPC. The presented patient cases from SPARTAN and the apalutamide compassionate use program are examples of the beneficial effects that apalutamide can achieve in the M0CRPC setting.

Schlüsselwörter

M0CRPC - Prostatakarzinom - Apalutamid - Härtefallprogramm - Fallbericht

Keywords

prostate cancer - M0CRPC - case report - compassionate use program - apalutamide

• Literatur

• 1 Scher HI. et al. Prevalence of Prostate Cancer Clinical States and Mortality in the United States: Estimates Using a Dynamic Progression Model. PLoS One 2015; 10: e0139440
• 2 Liede J. et al. International prevalence of nonmetastatic (M0) castration-resistant prostate cancer (CRPC). J Clin Oncol 2013; 31: e16052
• 3 Kirby M. et al. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011; 65: 1180-1192
• 4 DePuy V. et al. Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 2007; 15: 869-876
• 5 Bubendorf L. et al. Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000; 31: 578-583
• 6 McKay R. et al. Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases. Prostate Cancer Prostatic Dis 2017; 20: 276-282
• 7 Smith MR. et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 2918-2925
• 8 Smith MR. et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet 2012; 379: 39-46
• 9 Smith MR. et al. Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol 2013; 31: 3800-3806
• 10 Saad F. et al. A Population-based Study of the Association of Prostate-Specific Antigen Doubling Time (PSADT) with Metastasis-free Survival (MFS) and Overall Survival (OS) in Nonmetastatic Castration-Resistant Prostate Cancer (NMCRPC) Patients (PTS). J Urol 2018; PD10–04 199: e229
• 11 S3-Leitlinie zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinoms, Version 5.1 – Mai 2019 AWMF – Registernummer: 043/022OL. (letzter Zugriff: 09.11.2020) https://www.leitlinienprogramm-onkologie.de/leitlinien/prostatakarzinom/
• 12 Mottet M. et al. EAU-Guidelines Prostate Cancer. 2018 (letzter Zugriff: 09.11.2020) https://uroweb.org/wp-content/uploads/EAU-ESUR-ESTRO-SIOG-Guidelines-on-Prostate-Cancer-large-text-V2.pdf
• 13 Mottet M. et al. EAU-Guidelines Prostate Cancer. 2020 (letzter Zugriff: 09.11.2020) https://uroweb.org/guideline/prostate-cancer/
• 14 Bailey DE. et al. Psychosocial trajectories of men monitoring prostate-specific antigen levels following surgery for prostate cancer. Oncol Nurs Forum 2014; 41: 361-368
• 15 Smith MR. et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med 2018; 378: 1408-1418
• 16 Small EJ. et al. Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). ASCO 2020, Poster & Poster Discussion 5516. J Clin Oncol 2020; 38 (Suppl. 15) 5516
• 17 Payne HA. et al. Apalutamide for non-metastatic castration resistant prostate cancer (NMCRPC): a comparison of real-life experience from an international named patient program (NPP) vs the prior phase III clinical study. ESMO 2020, Abstract & Poster 630P. Ann Oncol 2020; 30 (Suppl. 04) S520